/
ALLO
$2.22+$0.09 (+4.23%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$735.2M
345M shares
52-week range
$0.98 – $4.46
36% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-23.86
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $114.1M | $156.0K | $95.0K | $22.0K | $0 |
| Cost of revenue | $0 | $5.0M | $11.5M | $0 | $14.3M | $0 | $0 | $12.4M |
| Gross profit | −$1.5M | −$5.0M | −$11.5M | $114.1M | −$14.1M | $95.0K | $22.0K | −$12.4M |
| Gross margin | — | — | — | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| R&D | $151.9M | $144.5M | $193.0M | $220.2M | $256.4M | $242.9M | $192.3M | $150.2M |
| Operating income | −$192.8M | −$202.0M | −$258.2M | −$180.2M | −$335.5M | −$327.7M | −$273.2M | −$206.9M |
| EBITDA | −$206.8M | −$179.9M | −$238.7M | −$171.6M | −$326.1M | −$313.1M | −$243.3M | −$177.5M |
| Net income | −$211.5M | −$184.6M | −$250.2M | −$182.1M | −$340.4M | −$327.3M | −$257.6M | −$190.9M |
| Net margin | — | — | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (diluted) | -2.36 | -1.83 | -2.08 | -1.34 | -2.38 | -2.09 | -1.32 | -0.87 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5000 | $-0.70 | $-0.85–$-0.60 | 8 |
| 2027 | $11M | $-0.75 | $-0.91–$-0.45 | 7 |
| 2028 | $78M | $-0.69 | $-1.09–$-0.29 | 10 |
| 2029 | $312M | $-0.11 | $-0.11–$-0.11 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Allogene Therapeutics, Inc. Common Stock
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
www.allogene.com- Employees
- 152
- IPO / List date
- Oct 11, 2018
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds ALLO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,139,328 | $5.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ALLO yet.
